Wednesday, November 18, 2026
FDA RECALLClass INovember 10, 2026

FDA Medical Device Class I: Tandem Diabetes Care, Inc. – Tandem Mobi Insulin Pump, Models: 1004004, 1010750, 1012676, 1012719, 1013655, 1

Affected Product:Tandem Mobi Insulin Pump, Models: 1004004, 1010750, 1012676, 1012719, 1013655, 1013656, 1013501, 1013700, 1014081, 1014801, 1014811, 1014813, 1014936, 1016911, 1016912, 1016913, 1016914, 1018075, 1018077, 1018078
Recalling Firm / Manufacturer:Tandem Diabetes Care, Inc.
Reference / Recall Number:Z-0316-2027
Distribution Scope:Worldwide - US Nationwide distribution including in the states of CA, FL, NC, OK, UT, WA, IL, PA, MN, VA, NY, IN, HI, OR, GA, MI, KS, CO, WI, SC, null, TX, NE, AZ, OH, NM, NV, MA, SD, IA, TN, ID, MD, RI, CT, NJ, ME, KY, MT, WV, VT, MS, AR, AL, DC, LA, MO, NH, PR, ND, AK, DE, WY and the country of Canada.
Executive Summary:

Class I issued for Tandem Mobi Insulin Pump, Models: 1004004, 1010750, 1012676, 1012719, 1013655, 1013656, 1013501, 1013700, 1014081, 10148. Tandem Diabetes Care, Inc. ( Tandem ) has identified that certain Tandem Mobi insulin pumps may generate false-positive occlusion alarms whe...

The FDA Center for Devices and Radiological Health (CDRH) has issued an official medical device recall determination for Tandem Mobi Insulin Pump, Models: 1004004, 1010750, 1012676, 1012719, 1013655, 1013656, 1013501, 1013700, 1014081, 1014801, 1014811, 1014813, 1014936, 1016911, 1016912, 1016913, 1016914, 1018075, 1018077, 1018078 produced by Tandem Diabetes Care, Inc..

Regulatory Recall Specification

  • Recall Number: Z-0316-2027
  • Recall Classification: Class I
  • Firm Name: Tandem Diabetes Care, Inc.
  • Current Status: Ongoing

Reason for Device Recall

Tandem Diabetes Care, Inc. ( Tandem ) has identified that certain Tandem Mobi insulin pumps may generate false-positive occlusion alarms when no actual insulin flow obstruction is present. Investigation determined that increased friction within the drive module can reduce available motor power and, under certain conditions, cause motor speed to fall below the occlusion detection threshold. As a result, the pump may incorrectly detect an occlusion condition and suspend insulin delivery. When an occlusion alarm occurs, insulin delivery remains suspended until the user acknowledges the alarm and resumes therapy. Repeated false-positive occlusion alarms, if not addressed promptly, may result in interruptions of insulin delivery that can increase the risk of elevated blood glucose levels. In severe cases, hyperglycemia may require medical intervention or hospitalization.

Clinical & Corrective Actions

Healthcare facilities and clinical engineering departments are advised to review the affected serial numbers and follow the manufacturer's field safety notice instructions.

Official Regulatory Docket:Open Agency Docket